Skip to main content Help with accessibility Skip to main navigation

Insulin glargine

Indication

Type 1 and Type 2 diabetes mellitus

For biosimilars see Insulin glargine biosimilar (Abasaglar®)

 

Green

Brand:

Lantus®

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Insulin glargine 100 units/mL (Lantus®) is recommended for use in patients with type 1 and type 2 diabetes mellitus.
Prescribing should be by brand name, followed by the concentration and recommended daily dose.
Lantus® brand is not a preferred product in the LSCMMG antihyperglycaemics guideline. Biosimilars of Insulin glargine are also available for the treatment of NEW patients and patients assessed to need a medication change. Treatment should normally be started with the least expensive drug.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Decisions of Lancashire local decision making groups

Pending
Pending
Amber 0
Pending
Pending
Amber 0
Pending
Pending
What do the colours mean?

Last Updated: 01 - Jan - 2016